TCF3-PBX1 Fusion Gene Qualitative PCR in Dubai, UAE | 650 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).

Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain and VIP Mobile Phlebotomy.

Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced qualitative PCR assay precisely identifies the TCF3-PBX1 (E2A-PBX1) fusion gene, a key biomarker in B‑cell acute lymphoblastic leukemia (B‑ALL), enabling targeted therapy decisions. The test uses real‑time PCR with melt curve analysis for highly specific detection.

Feature	Our Test (TCF3-PBX1 PCR)	Closest Alternative (Outside Lab)
Precision	99.9% Sensitivity, ISO 9001:2015 Validated	Variable, often lacking accreditation
Methodology	Qualitative Real-Time PCR (qPCR) with Melt Curve Analysis	Conventional PCR or non-validated assays
Turnaround Time	Sample Mon/Thu by 11 am; Report Wed/Sat	Often 7+ days, delays common

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), Consultant Medical Genetics, shares: “As a specialist in medical genetics, I confirm that detection of the TCF3-PBX1 fusion gene is critical for risk stratification in pediatric and adult B‑ALL. A positive result indicates a high‑risk subtype requiring intensive chemotherapy and possibly targeted agents. However, a negative result does not exclude other genetic aberrations — comprehensive molecular profiling remains essential.”

Important Medical Advisory

Do not discontinue or alter any prescribed therapy without consulting your treating physician. This test is a diagnostic aid and does not replace continuous medical supervision.

Exclusion Criteria & Emergency Red Flags

Exclusion: Hemolyzed, clotted, or improperly stored (frozen) samples; incomplete clinical history; prenatal diagnosis not supported.
ER Red Flags: If you experience fever >38.3°C, severe bleeding, sudden neurological changes, or severe bone pain before receiving results, seek immediate emergency care.

Patient FAQ & Clinical Guidance

1. What does a positive TCF3-PBX1 PCR result mean?

A positive result confirms the presence of the TCF3-PBX1 fusion gene, indicating a high‑risk subtype of B‑cell acute lymphoblastic leukemia. This finding guides treatment decisions, including intensive chemotherapy and potential targeted therapies.

2. How should I prepare for the test?

No special preparation is needed apart from providing a mandatory clinical history and avoiding sample freezing. A routine blood draw is sufficient.

3. Is home blood collection available for this test?

Yes, our ISO‑certified phlebotomists offer paid hospital‑grade home collection across all Emirates from 8 AM to 11 PM, using temperature‑controlled cold‑chain logistics.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Compliance: This test operates under strict adherence to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical and consent procedures follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your data is encrypted and processed within DHA‑licensed infrastructure.

Clinical & Logistical Metadata

Test Name	TCF3-PBX1 Fusion Gene Qualitative PCR
Price (AED)	650
Turnaround Time	2–3 Business Days (Sample submission Mon/Thu before 11 AM yields report Wed/Sat; other times +1 day)
Sample Type / Matrix	Peripheral Blood (Whole Blood) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available (8 AM – 11 PM daily)
Methodology Used	Qualitative Real‑Time PCR (qPCR) with Melt Curve Analysis
ICD-10-CM Code	C91.00
LOINC Code	79556-2
DHA Facility License & Laboratory Address	License No. 1143 \| DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE